Cardiac Amyloidosis Clinical Trials
The cardiac amyloidosis team at Cedars-Sinai is one of the few programs on the West Coast evaluating new treatments designed to reduce or stop heart damage caused by cardiac amyloidosis. You have the opportunity to take part in these efforts through clinical trials. We lead and participate in trials testing promising new drug therapies. These drugs may be the key to helping cardiac amyloidosis patients survive longer and with a better quality of life.
Transthyretin mediated amyloid cardiomyopathy
- 18-90 years old
- Willing to be genetically tested for mutations in the TTR gene
Transthyretin (TTR) amyloidosis
- Not pregnant or lactating
The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called ION-682884 in individuals who have transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a disease caused by change in a protein called transthyretin (TTR).